background
aim
cyclophilininhibitor
potent
antivir
activ
hepat
c
viru
hcv
promis
candid
broadspectrum
antivir
therapi
cyclosporin
csa
act
immunosuppress
block
cell
activ
antigen
present
alisporivir
nonimmunosuppress
csa
analog
clinic
develop
inhibit
cell
activ
studi
explor
impact
alisporivir
antigen
present
method
hepatoma
cell
endogen
express
epitoperestrict
major
histocompat
complexclass
mhci
allel
constitut
express
viral
antigen
establish
studi
impact
cyclophilininhibitor
antigen
present
antigenspecif
cell
activ
mhci
surfac
express
measur
quantifi
antigen
present
result
work
establish
novel
cell
cultur
model
studi
antigen
present
liverderiv
cell
authent
regul
antigen
present
ensur
action
proand
antiinflammatori
cytokin
alisporivir
pretreat
stimul
antigen
present
hepatoma
target
cell
lead
enhanc
antigenspecif
cell
activ
alisporivir
well
panel
cyclophilininhibitor
induc
increas
mhci
microglobulin
surfac
sever
cell
line
drug
neither
enhanc
mhci
transcript
protein
level
affect
surfac
express
protein
protein
traffick
gener
proteasomeinhibitor
complet
block
alisporivirdirect
enhanc
surfac
mhci
suggest
influenc
drug
peptideavail
conclus
alisporivir
stimul
antigen
present
induc
enhanc
mhci
surfac
express
therebi
promot
antigenspecif
cell
activ
immunostimulatori
function
might
contribut
antivir
activ
nonimmunosuppress
cyclophilininhibitor
hepat
c
viru
hcv
establish
persist
high
rate
patient
result
million
chronic
infect
worldwid
recent
year
direct
act
antivir
host
target
antivir
identifi
allow
new
opportun
antivir
therapi
patient
chronic
infect
hcv
characterist
host
target
antivir
includ
broad
genotyp
coverag
high
barrier
resist
one
compound
cyclophilin
cyp
inhibitor
alisporivir
target
cellular
protein
hcv
host
factor
cyclophilin
cypa
clinic
develop
hcv
therapi
furthermor
due
involv
cyclophilin
lifecycl
broad
rang
virus
like
human
immunodefici
viru
hiv
hepat
b
viru
hbv
sever
coronavirus
alisporivir
repres
promis
candid
panvir
therapi
drug
analog
cyclic
undecapeptid
cyclosporin
csa
block
cell
activ
form
ternari
complex
togeth
cypa
phosphatas
calcineurin
addit
csa
suppress
major
histocompat
complexclass
mhci
depend
antigen
present
poorli
defin
mechan
structur
alisporivir
differ
two
amino
acid
residu
immunosuppress
csa
abrog
inhibitori
effect
cell
activ
howev
effect
antigen
present
clarifi
far
recent
establish
immunolog
model
character
antivir
respons
hcvspecif
cell
activ
hepatoma
cell
harbor
selfrepl
hcv
replicon
assay
serv
analyz
antivir
effici
cell
respons
use
gain
insight
mhci
antigen
present
limit
due
ectop
express
mhci
engin
liver
cell
endogen
express
epitoperestrict
mhci
allel
ectop
express
epitopematch
hcv
protein
therebi
adapt
initi
model
quantifi
antigen
present
alisporivir
nonimmunosuppress
cypinhibitor
stimul
antigen
present
upregul
mhci
surfac
express
result
induct
enhanc
antigenspecif
cell
respons
find
point
addit
therapeut
benefit
applic
cypinhibitor
antivir
mediat
enhanc
immun
respons
cell
line
hepat
origin
cell
line
nonhepat
origin
hek
hela
cultur
modifi
essenti
medium
dmem
life
technolog
darmstadt
germani
supplement
mm
lglutamin
mm
nonessenti
amino
acid
uml
penicillin
lgml
streptomycin
life
technolog
fetal
calf
serum
fc
cell
describ
previous
cell
subclon
human
hepatoma
cell
line
gener
cure
cell
harbor
persist
hcv
replicon
csa
daclatasvir
heparg
cell
cultur
william
e
medium
life
technolog
supplement
lgml
insulin
lm
hydrocortison
hemisuccin
sigma
aldrich
steinheim
germani
uml
penicillin
uml
streptomycin
fc
em
specif
cell
clone
gener
limit
dilut
sort
tet
cell
previous
describ
cell
incub
incub
humid
co
alisporivir
novarti
basel
switzerland
dissolv
mgml
dmso
detail
inform
inhibitor
found
supplementari
materi
method
detail
descript
cell
cocultiv
assay
publish
earlier
brief
cell
cocultur
target
cell
one
well
well
dish
target
cell
wash
extens
cocultur
remov
residu
drug
amount
handl
peptid
alydvvskl
biosynthan
berlin
germani
describ
previous
upon
h
cocultur
effector
target
e
ratio
cell
stain
intracellular
ifnc
surfac
express
analyz
bd
facscanto
ii
becton
dickinson
new
jersey
usa
data
analyz
use
flowjo
softwar
tree
star
usa
stain
surfac
protein
cell
seed
drug
treatment
detach
day
seed
result
cell
cell
resuspend
icecold
pb
bovin
serum
albumin
pb
bsa
contain
primari
antibodi
individu
work
dilut
h
incub
cell
wash
twice
taken
icecold
pb
bsa
contain
goatantimous
antibodi
label
phycoerythrin
pe
santa
cruz
dalla
usa
incub
h
dark
cell
wash
twice
resuspend
icecold
pb
analyz
bd
facscalibur
bd
bioscienc
new
jersey
usa
wash
step
perform
icecold
pb
data
analyz
use
flowjo
softwar
tree
star
usa
primari
antibodi
respect
concentr
use
studi
lgml
r
system
minneapoli
canada
lgml
abcam
antihlaa
lgml
abcam
cambridg
uk
microglobulin
lgml
antihlaa
b
c
lgml
biolegend
london
uk
isotyp
control
antibodi
mous
biolegend
mous
r
system
wiesbaden
germani
condit
data
least
cell
collect
stain
intracellular
ifnc
surfac
perform
describ
previous
statist
analysi
twotail
pair
test
perform
use
graphpad
prism
softwar
graphpad
softwar
inc
la
jolla
ca
detail
statist
test
indic
figur
legend
p
p
p
transcriptom
data
access
via
vitro
immunolog
model
measur
function
antigen
present
first
aim
studi
establish
cell
cultur
model
allow
quantit
assess
function
antigen
present
hepatocyt
end
modifi
previous
establish
assay
employ
cocultiv
hcvspecif
hlaa
cell
hepatoma
cell
ectop
express
mhci
allel
hlaa
gener
physiolog
environ
use
hepatoma
cell
line
endogen
express
hlaa
stabli
express
epitopematch
protein
em
em
epitopematch
fig
peptid
present
cellular
surfac
via
hlaa
result
antigenspecif
cell
activ
cocultur
hlaa
em
transduc
hepatoma
cell
cell
concomit
product
variou
effector
molecul
fig
importantli
cocultur
assay
encompass
whole
antigen
present
process
physiolog
regul
mhci
express
process
endogen
antigen
surfac
present
via
mhci
therefor
modif
step
pathway
significantli
impact
effici
function
antigen
present
detect
chang
cell
activ
test
two
hlaa
hepatoma
cell
line
character
either
high
low
hlaa
express
level
supplementari
fig
cell
activ
upon
cocultur
em
cell
could
enhanc
pretreat
cell
ifnc
wellknown
stimul
mhci
antigen
present
supplementari
fig
therefor
cell
suitabl
model
sinc
condit
enhanc
antigen
present
would
miss
contrast
em
cell
gave
rise
signific
portion
activ
cell
lower
fig
possibl
due
lower
mhci
express
level
supplementari
fig
basic
cell
activ
rate
cocultiv
assay
vari
differ
experi
compar
fig
due
passag
number
preactiv
statu
cell
still
modulatori
effect
cytokin
remain
independ
baselin
activ
level
data
shown
upon
confirm
cytokin
receptor
express
cell
supplementari
tabl
founder
cell
line
use
sever
proinflammatori
cytokin
tnfa
antiinflammatori
cytokin
tgfb
type
ii
iii
interferon
ifna
ifnc
ifnk
evalu
physiolog
regul
antigen
present
system
defin
dynam
rang
pretreat
cell
tnfa
led
enhanc
cell
activ
tgfb
expect
stimul
effect
fig
howev
type
ii
ifn
wellknown
stimul
antigen
present
well
type
iii
ifn
report
ifnclik
effect
hepatocyt
stimul
function
antigen
present
cell
even
stronger
fig
furthermor
alter
hlaa
surfac
express
target
cell
upon
treatment
differ
cytokin
correl
chang
antigen
present
potenc
fig
conclus
endogen
process
peptid
present
cell
gave
rise
hlaa
antigenspecif
cell
activ
hlaa
surfac
express
cell
allow
physiolog
modul
function
antigen
present
cytokin
like
reflect
low
mhci
express
level
human
liver
overal
model
therefor
appear
suitabl
detect
immunomodulatori
effect
antigen
present
csa
report
block
cell
activ
inhibit
calcineurin
antagon
antigen
present
csa
analog
alisporivir
suppress
cell
activ
howev
whether
alisporivir
impair
antigen
present
investig
fig
therefor
pretreat
hepatoma
target
cell
endogen
express
hlaa
stabli
express
epitopematch
hcv
protein
em
cocultur
hlaa
em
specif
cell
clone
antigenspecif
cell
activ
induc
bind
cell
receptor
tcr
em
peptidemhci
complex
stimul
ifncproduct
measur
indirect
readout
antigen
present
capac
target
cell
b
variou
cytokin
stimul
antigen
present
cell
measur
cocultiv
assay
cell
express
em
pretreat
indic
cytokin
cocultur
cell
cell
stain
intracellular
ifnc
surfac
upper
right
quadrant
includ
percentag
activ
ifncproduc
cell
depict
result
one
repres
experi
n
c
cytokin
stimul
antigen
present
enhanc
mhci
surfac
express
cell
treat
indic
cytokin
stain
hlaa
data
present
histogram
shade
area
isotyp
control
diagram
right
present
mean
fold
chang
geometr
mean
fluoresc
intens
geomfi
two
independ
experi
n
er
endoplasm
reticulum
hla
human
leukocyt
antigen
microglobulin
tap
transport
associ
antigen
process
tcr
cell
receptor
antigen
present
cocultur
hcvspecif
cell
target
cell
detach
wash
extens
avoid
drug
carryov
cocultur
fig
ifnc
pretreat
cell
preload
cell
peptid
serv
posit
control
fig
result
strong
activ
cell
expect
pretreat
csa
abolish
antigen
present
cell
fig
strike
contrast
alisporivir
pretreat
target
cell
dosedepend
increas
percentag
activ
cell
suggest
stimul
antigen
present
capac
alisporivir
fig
use
lm
alisporivir
subsequ
experi
sinc
concentr
rang
regard
physiolog
relev
base
efficaci
inhibit
hcv
replic
vitro
vivo
next
cell
pretreat
differ
time
alisporivir
explor
kinet
immunostimul
h
pretreat
minor
effect
wherea
h
treatment
increas
cell
activ
reach
plateau
remain
stabl
least
day
fig
argu
slow
accumul
process
increas
antigen
present
alisporivir
percentag
activ
cell
enhanc
approxim
upon
alisporivir
treatment
experi
compar
fig
summari
demonstr
alisporivir
immunostimulatori
effect
antigen
present
human
hepatoma
cell
possibl
support
antivir
activ
vivo
alisporivir
enhanc
mhci
surfac
express
cell
line
hepat
nonhepat
origin
far
detect
immunostimulatori
effect
alisporivir
use
cell
activ
indirect
readout
antigen
present
assum
amount
mhcipeptid
cell
surfac
limit
factor
antigenspecif
cell
activ
measur
surfac
hlaa
cell
differ
time
alisporivir
treatment
fig
b
inde
alisporivir
slowli
continu
enhanc
hlaa
surfac
express
time
fig
b
assess
whether
effect
restrict
cell
analyz
liverderiv
cell
line
fig
sinc
cell
line
apart
endogen
express
hla
allel
differ
hlaa
measur
surfac
express
inde
significantli
upregul
heparg
h
alisporivir
treatment
compar
dmso
control
fig
analog
result
obtain
mhci
specif
antibodi
supplementari
fig
b
furthermor
alisporivir
treatment
significantli
enhanc
mhci
surfac
express
lung
epitheli
cell
similar
trend
observ
cell
line
nonhepat
origin
supplementari
fig
summari
upregul
mhci
surfac
express
alisporivir
restrict
particular
cell
line
found
cell
variou
origin
alisporivir
affect
mhci
mrna
protein
level
gener
impact
protein
secret
next
want
address
whether
alisporivirinduc
enhanc
mhci
surfac
express
due
chang
mhci
mrna
protein
express
level
ifnc
expect
increas
mrna
express
hlab
effect
detect
alisporivir
fig
supplementari
fig
line
data
mhci
protein
level
heparg
cell
alter
alisporivir
contrast
ifnc
treatment
fig
addit
found
slight
argu
mechan
involv
regul
hla
gene
express
fig
enhanc
mhci
surfac
express
alisporivir
could
also
caus
gener
effect
protein
surfac
express
line
previou
studi
report
upregul
pathway
associ
protein
traffick
csa
analog
howev
neither
surfac
express
ifncreceptor
chain
type
transmembran
protein
like
mhci
achain
like
mhci
cotransl
glycosyl
insid
endoplasm
reticulum
transport
golgi
cell
surfac
affect
alisporivir
treatment
fig
gener
effect
cellular
transport
exclud
alisporivir
affect
gaussialuciferas
gluc
secret
transferrin
fig
summari
data
suggest
specif
enhanc
mhci
surfac
express
upon
alisporivir
treatment
neither
caus
induct
basal
mhci
express
gener
effect
cellular
protein
traffick
also
found
evid
strong
impact
alisporivir
mhci
intern
passag
golgi
wonder
alisporivir
induc
effect
depend
peptid
avail
sinc
peptid
amount
limit
factor
mhci
antigen
present
inde
observ
complet
inhibit
mhci
upregul
alisporivir
combin
proteasomeinhibitor
wherea
basal
mhci
surfac
express
affect
condit
fig
result
argu
enhanc
surfac
express
primarili
peptideload
mhci
critic
role
peptideavail
suggest
peptidegener
potenti
target
alisporivir
interestingli
recent
studi
observ
upregul
surfac
mhci
upon
activ
mediat
enhanc
express
endoplasm
reticulum
aminopeptidas
transport
associ
antigen
process
inde
detect
minor
insignific
upregul
mrna
alisporivir
fig
found
chang
protein
level
activ
statu
fig
data
shown
conclus
alisporivir
led
upregul
peptideload
mhci
complex
possibl
due
enhanc
peptideavail
yet
defin
mechan
search
molecular
target
alisporivir
first
focus
cypa
cypb
common
best
studi
cyp
famili
like
member
show
compar
express
cell
supplementari
tabl
howev
simultan
knockdown
cypa
b
significantli
affect
mhci
surfac
express
untreat
alisporivir
treat
cell
fig
c
data
shown
suggest
abund
cyp
main
determin
mediat
surfac
accumul
mhci
cypinhibitor
cover
broad
rang
cellular
target
includ
adenosin
triphosph
bind
cassett
abc
transport
na
taurochol
cotransport
polypeptid
ntcp
calcineurin
therefor
test
panel
compound
differ
inhibit
profil
effect
mhci
surfac
express
use
noncytotox
concentr
supplementari
fig
csa
structur
unrel
cypinhibitor
sanglifehrin
sfa
stimul
signific
increas
hlaa
mhci
surfac
express
extent
similar
alisporivir
fig
e
supplementari
fig
b
argu
cypinhibit
underli
caus
agreement
assumpt
abctransport
inhibitor
reversan
piperin
strongli
impact
amount
surfac
hlaa
mhci
inhibit
differ
group
peptidylprolyl
ci
tran
isomeras
fig
e
supplementari
fig
b
contrast
cyclic
undecapeptid
cyclosporin
h
csh
reduc
affin
least
common
cyp
induc
signific
upregul
hlaa
mhci
surfac
express
similar
degre
alisporivir
fig
e
supplementari
fig
b
summari
cyclophilin
like
target
respons
upregul
mhci
surfac
express
studi
cypinhibitor
mediat
effect
antigen
present
modifi
previous
develop
immunolog
model
use
cell
intrins
express
hlaa
constitut
ectop
express
low
activ
cell
provid
dynam
rang
downregulatori
effect
addit
proinflammatori
cytokin
ifn
enhanc
mhci
surfac
express
stimul
cell
cocultur
argu
physiolog
regul
function
antigen
present
cell
use
model
abl
valid
propos
ifnclik
effect
hepatocyt
csa
shown
inhibit
antigen
present
howev
found
csa
analog
alisporivir
exert
immunostimulatori
effect
mediat
slow
enhanc
mhci
surfac
express
time
accompani
higher
percentag
activ
hcvspecif
cell
interestingli
csa
also
increas
mhci
surfac
express
still
entir
block
function
antigen
present
cell
yet
defin
mechan
upregul
mhci
surfac
express
confirm
panel
cell
line
divers
origin
due
chang
total
mhci
express
level
furthermor
alisporivir
specif
upregul
mhci
sinc
neither
express
surfac
protein
overal
protein
secret
modifi
also
could
find
evid
impact
alisporivir
mhci
traffick
endocytosi
degrad
although
exclud
miss
subtl
effect
mhci
transport
dynam
due
limit
avail
assay
still
favor
mechan
mediat
enhanc
peptid
amount
avail
mhci
load
sinc
stimulatori
effect
alisporivir
regular
mhci
surfac
express
complet
abrog
proteasomeinhibitor
hypothes
inhibit
chaperonelik
function
cyp
alisporivir
might
enhanc
peptid
pool
avail
present
mhci
increas
amount
unfold
protein
still
studi
requir
clarifi
mechan
alisporivir
stimul
mhci
surfac
express
cyp
group
peptidylprolyl
ci
tran
isomeras
includ
least
famili
member
human
poorli
studi
regard
inhibit
cypinhibitor
molecular
function
cypinhibitor
restrict
cyp
also
act
addit
target
like
abctransport
calcineurin
involv
cyp
mhci
surfac
upregul
support
fact
cypinhibitor
test
increas
mhci
surfac
express
contrast
inhibitor
differ
class
peptidylprolyl
ci
tran
isomeras
two
abctransport
inhibitor
reversan
piperin
howev
csh
csa
analog
reduc
affin
best
studi
cyp
induc
phenotyp
observ
csa
alisporivir
sfa
wherea
sirnamedi
knockdown
cypa
cypb
common
cyp
affect
mhci
surfac
express
well
individu
knockdown
sever
cyp
data
shown
altogeth
result
either
point
potenti
role
less
studi
cyp
still
block
compound
redund
role
mani
cyp
due
varieti
potenti
target
possibl
involv
sever
cyp
analog
function
attempt
defin
specif
cyp
potenti
involv
regul
mhci
surfac
express
reason
due
high
abund
mani
cyp
neither
carri
cypoverexpress
alisporivir
well
nonimmunosuppress
cypinhibitor
like
clinic
develop
antivir
therapi
chronic
hcvinfect
patient
repres
potenti
broadspectrum
antivir
drug
sinc
mani
virus
depend
cypa
host
factor
base
vitro
data
specul
alisporivir
exert
immunostimulatori
effect
hepatocyt
antigen
present
therapi
chronic
hcvinfect
patient
might
complement
antivir
properti
support
effici
adapt
immun
respons
stimul
antigen
present
capac
hepatocyt
normal
express
low
level
mhci
might
promot
recognit
infect
cell
cell
final
contribut
clearanc
previous
report
ifnfre
therapi
hcvinfect
patient
direct
act
antivir
ifnbas
treatment
potenti
restor
function
cell
respons
presum
lower
high
antigen
level
may
support
cell
exhaust
along
line
seem
plausibl
alisporivir
appli
ifnfre
regimen
could
restor
cell
respons
even
effici
addit
promot
clearanc
infect
cell
cell
via
enhanc
function
antigen
present
inde
immunomodulatori
activ
peripher
blood
mononuclear
cell
hcvinfect
patient
observ
clinic
trial
cypinhibitor
gain
insight
contribut
immunostimulatori
effect
cypinhibitor
cure
hcv
infect
futur
clinic
studi
also
monitor
develop
cell
respons
therapi
altern
test
drug
suitabl
anim
model
allow
thorough
quantif
cell
respons
could
shed
light
impact
alisporivir
adapt
immun
respons
variou
organ
vivo
conclus
could
demonstr
nonimmunosuppress
cypinhibitor
strike
contrast
csa
increas
function
antigen
present
upregul
mhci
surfac
express
importantli
enhanc
antigen
present
upon
alisporivir
treatment
might
also
support
clearanc
virus
sensit
cypinhibitor
project
fund
grant
deutsch
forschungsgemeinschaft
vl
rt
cnh
